Re: Farmas USA
SGYP
Ana veamos que sale el proximo 12 ,pero de cortos van bien cargadita , ya eso me da miedo, asi que un par de dias antes y cuando recoja los profits que espero de mi posicion a 1.65 creo que me voy a salr , pero sigo pensado que Trulance va a prosperar mucho este Q2 y los que vienen tambien ,ademas de la G News de hoy sobre Uroguanylin que le dan otro valor potencia esta accion.
--
This is an exciting day for Synergy and for the broader GI community,” said Patrick H. Griffin, M.D., Chief Medical Officer at Synergy Pharmaceuticals Inc.
.....These results suggest a novel pathophysiological hypothesis in which chronic constipation may reflect a paracrine hormone insufficiency of pro-uroguanylin in the small intestine. The correlative therapeutic hypothesis suggests that this pathophysiology can be reversed by oral supplementation with a uroguanylin analog such as plecanatide
----
Another metric called "number needed to harm" or NNH, showing the number of patients that need to be treated before seeing a detrimental effect (high number is better), favored TRULANCE. Its NNH value was almost 3x higher than its NNT values, implying that treated patients are three times more likely to experience a beneficial effect before experiencing a harmful effect.
The NNH values for LINZESS were lower than the NNT values implying that patients receiving either dose would most likely experience a harmful effect before experiencing a beneficial effect.